Eric Ruby

443 total citations
10 papers, 279 citations indexed

About

Eric Ruby is a scholar working on Epidemiology, Hepatology and Organic Chemistry. According to data from OpenAlex, Eric Ruby has authored 10 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 5 papers in Hepatology and 1 paper in Organic Chemistry. Recurrent topics in Eric Ruby's work include Hepatitis C virus research (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Hepatitis B Virus Studies (4 papers). Eric Ruby is often cited by papers focused on Hepatitis C virus research (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Hepatitis B Virus Studies (4 papers). Eric Ruby collaborates with scholars based in United Kingdom, Australia and Malaysia. Eric Ruby's co-authors include Richard J. Colonno, Man‐Fung Yuen, Kosh Agarwal, William Sievert, Uri Lopatin, Kumar Visvanathan, Sang Hoon Ahn, Wendy Cheng, Dong Joon Kim and Young‐Suk Lim and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Hepatology and The Journal of Antibiotics.

In The Last Decade

Eric Ruby

10 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Ruby United Kingdom 6 106 106 105 54 50 10 279
H.H. Jo South Korea 9 184 1.7× 59 0.6× 71 0.7× 130 2.4× 26 0.5× 17 341
T. Igarashi Japan 7 159 1.5× 17 0.2× 52 0.5× 144 2.7× 43 0.9× 11 392
Satoru Kawai Japan 10 6 0.1× 13 0.1× 24 0.2× 41 0.8× 6 0.1× 40 281
Fraser Gray United Kingdom 6 8 0.1× 373 3.5× 388 3.7× 28 0.5× 2 0.0× 9 469
Takeshi Taniguchi Japan 7 41 0.4× 5 0.0× 11 0.1× 245 4.5× 7 0.1× 10 332
Gaku Suzuki Japan 9 85 0.8× 1 0.0× 17 0.2× 76 1.4× 4 0.1× 34 360
J. Akiyama Japan 11 25 0.2× 3 0.0× 27 0.3× 23 0.4× 1 0.0× 27 382
H. Adachi Japan 11 4 0.0× 7 0.1× 15 0.1× 102 1.9× 9 0.2× 28 340

Countries citing papers authored by Eric Ruby

Since Specialization
Citations

This map shows the geographic impact of Eric Ruby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Ruby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Ruby more than expected).

Fields of papers citing papers by Eric Ruby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Ruby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Ruby. The network helps show where Eric Ruby may publish in the future.

Co-authorship network of co-authors of Eric Ruby

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Ruby. A scholar is included among the top collaborators of Eric Ruby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Ruby. Eric Ruby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Mannowetz, Nadja, Stewart W. McCallum, Eric Ruby, et al.. (2025). Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529. Communications Medicine. 5(1). 279–279. 1 indexed citations
2.
Yuen, Man‐Fung, Kosh Agarwal, Edward Gane, et al.. (2019). Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ˜The œLancet. Gastroenterology & hepatology. 5(2). 152–166. 81 indexed citations
3.
Gane, Edward, Christian Schwabe, Eric Ruby, et al.. (2019). LBP-12-Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers. Journal of Hepatology. 70(1). e146–e147. 2 indexed citations
4.
5.
Esmat, Gamal, Tamer Elbaz, Maissa El Raziky, et al.. (2017). Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. Journal of Hepatology. 68(1). 53–62. 12 indexed citations
6.
7.
Lalezari, Jacob, Pamela Vig, Jerry O. Stern, et al.. (2014). O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN. Journal of Hepatology. 60(1). S27–S27. 3 indexed citations
8.
Atwal, Karnail S., Brian C. O'Reilly, Eric Ruby, et al.. (1987). Substituted 1,2,3,4-tetrahydroaminonaphthols: antihypertensive agents, calcium channel blockers, and adrenergic receptor blockers with catecholamine-depleting effects. Journal of Medicinal Chemistry. 30(4). 627–635. 31 indexed citations
9.
Liu, Wen-Chih, et al.. (1984). Phenacein - an angiotensin-converting enzyme inhibitor produced by a streptomycete. II. Isolation, structure determination and synthesis.. The Journal of Antibiotics. 37(11). 1313–1319. 9 indexed citations
10.
Ruby, Eric, et al.. (1965). Ternary phase equilibria in transition metal-boron-carbon-silicon systems. Medical Entomology and Zoology. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H.H. Jo Breakdown of academic impact, for papers by T. Igarashi Breakdown of academic impact, for papers by Satoru Kawai Breakdown of academic impact, for papers by Fraser Gray Breakdown of academic impact, for papers by Takeshi Taniguchi Breakdown of academic impact, for papers by Gaku Suzuki Breakdown of academic impact, for papers by J. Akiyama Breakdown of academic impact, for papers by H. Adachi
Rankless by CCL
2026